| Literature DB >> 32851253 |
Abstract
IMPORTANCE: Central nervous system infection is a severe illness in children. Little is known about the long-term outcome in children with central nervous system infection of various etiologies.Entities:
Keywords: Central nervous system infection; Children; Long‐term; Outcome; Prognosis
Year: 2018 PMID: 32851253 PMCID: PMC7331314 DOI: 10.1002/ped4.12054
Source DB: PubMed Journal: Pediatr Investig ISSN: 2574-2272
Demographic features of patients with CNS infection, by causative agent
| Causative Agent | Patients N (%) | Months of age (Range) | Favorable outcome N (%) | CNS infection‐related deaths N (%) |
|---|---|---|---|---|
| All patients | 139 (100) | 46 (1–180) | 109 (78) | 8 (6) |
| HSV | 13 (9) | 23 (4–93) | 3 (23) | 2 (15) |
| Enterovirus | 12 (9) | 58 (3–112) | 11 (92) | 1 (8) |
| JEV | 5 (4) | 56 (29–96) | 1 (20) | 2 (40) |
| Other virus | 43 (31) | 74 (7–170) | 42 (98) | 0 |
|
| 6 (4) | 35 (2–163) | 5 (83) | 0 |
| Other bacteria | 49 (35) | 19 (1–165) | 41 (84) | 3 (6) |
|
| 4 (3) | 144 (120–180) | 2 (50) | 0 |
|
| 4 (3) | 5 (3–8) | 3 (75) | 0 |
|
| 3 (2) | 90 (56–151) | 2 (67) | 0 |
HSV, herpes simplex virus; JEV, Japanese Encephalitis Virus; S. pneumoniae, Streptococcus pneumoniae; M. pneumoniae, Mycoplasma pneumoniae; C. albicans, Candida albicans; C. neoformans, Cryptococcus neoformans.
Other viruses included mumps virus (N = 1), Epstein‐Barr virus (N = 4) and probable viral meningitis and/or encephalitis (N = 38).
Other bacteria included Klebsiella pneumoniae (N = 2), Escherichia coli (N = 2), Streptococcus agalactiae (N = 2), Streptococcus intermedius (N = 2) and probable bacterial meningitis (N = 41).
Univariate analysis of factors associated with long term outcome
| Variables | All patients | Favorable outcome | Poor outcome |
|
|---|---|---|---|---|
| Numbers | 139 | 109 | 30 | |
| Age (month) | 46.6 ± 48.6 | 51.6 ± 50.3 | 28.7 ± 37.3 | 0.06 |
| Living in rural areas, N (%) | 68 (49) | 50 (46) | 18 (60) | 0.17 |
| Days from onset of illness to hospital admission | 12.2 ± 8.1 | 13.2 ± 9.2 | 10.2 ± 5.3 | 0.09 |
| Length of hospital stay (day) | 26.4 ± 20.4 | 23.1 ± 14.2 | 38.4 ± 32.3 | 0.16 |
| Body temperature | 38.8 ± 0.8 | 38.7 ± 0.8 | 38.9 ± 0.7 | 0.27 |
| Initial seizures during acute phase, N (%) | ||||
| No | 61 (44) | 57 (52) | 4 (13) | <0.01 |
| Single | 17 (12) | 15 (14) | 2 (7) | |
| Recurrent or status epilepticus | 61 (44) | 37 (34) | 24 (80) | |
| Coma during acute phase, N (%) | ||||
| No | 110 (79) | 97 (89) | 13 (43) | <0.01 |
| Yes | 29 (21) | 12 (11) | 17 (57) | |
| Steroid treatment, N (%) | ||||
| Yes | 49 (35) | 34 (31) | 15 (50) | 0.06 |
| No | 90 (65) | 75 (69) | 15 (50) | |
| CRP (mg/L) | 41.8 ± 66.0 | 41.9 ± 69.1 | 41.7 ± 53.9 | 0.17 |
| CSF parameters | ||||
| Leukocyte count (×106/L) | 2428 ± 2086 | 2814 ± 2353 | 1026 ± 2471 | 0.75 |
| Protein level (g/ml) | 881.6 ± 869.3 | 795.4 ± 756.4 | 1194.8 ± 1155.7 | 0.05 |
| Pure spikes in electroencephalogram during acute phase, N (%) | ||||
| Yes | 26 (19) | 13 (12) | 13 (43) | <0.01 |
| No | 113 (81) | 96 (88) | 17 (57) | |
| Parenchymal involvement in brain imaging, N (%) | ||||
| Yes | 52 (37) | 29 (27) | 23 (77) | <0.01 |
| No | 87 (63) | 80 (73) | 7 (23) | |
| Mechanical ventilation, N (%) | ||||
| Yes | 8 (6) | 2 (2) | 6 (20) | <0.01 |
| No | 131 (94) | 107 (98) | 24 (80) | |
| HSVE, N (%) | ||||
| Yes | 13 (9) | 3 (3) | 10 (33) | <0.01 |
| No | 126 (91) | 106 (97) | 20 (67) | |
HSVE, herpes simplex virus encephalitis; CRP, C‐reactive protein; CSF, cerebrospinal fluid.
Sequelae in patients with a GOS‐E Peds score < 7, by causative agent [N (%)]
| Signs | All patients with GOS‐E Peds < 7(N = 129) | HSVE (N = 10) | Enterovirus (N = 11) | Other virus (N = 45) |
| Other bacteria (N = 46) |
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| Headache, dizziness | 3 (2) | 0 | 0 | 2 (4) | 0 | 0 | 1 (25) | 0 | 0 |
| Nausea, vomiting | 1 (1) | 0 | 0 | 0 | 0 | 0 | 1 (25) | 0 | 0 |
| Irritability | 12 (9) | 2 (20) | 2 (18) | 1 (2) | 0 | 3 (7) | 2 (50) | 0 | 2 (67) |
| Anxiety | 1 (1) | 0 | 0 | 1 (2) | 0 | 0 | 0 | 0 | 0 |
| Depression | 1 (1) | 0 | 0 | 0 | 0 | 1 (2) | 0 | 0 | 0 |
| Trouble concentrating | 21 (16) | 5 (50) | 2 (18) | 7 (16) | 0 | 5 (11) | 1 (25) | 1 (25) | 0 |
| Memory impairment | 13 (10) | 4 (40) | 1 (9) | 2 (4) | 1 (17) | 4 (9) | 0 | 1 (25) | 0 |
| Disorientation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Limb paralysis | 15 (12) | 3 (30) | 0 | 5 (11) | 1 (17) | 2 (4) | 2 (50) | 1 (25) | 1 (33) |
| Ataxia | 9 (7) | 3 (30) | 0 | 1 (2) | 0 | 3 (7) | 1 (25) | 1 (25) | 0 |
| Facial palsy | 1 (1) | 0 | 0 | 0 | 1 (17) | 0 | 0 | 0 | 0 |
| Speech disorders | 12 (9) | 4 (40) | 1 (9) | 1 (2) | 1 (17) | 4 (9) | 1 (25) | 0 | 0 |
| Visual impairment | 3 (2) | 0 | 0 | 0 | 0 | 1 (2) | 0 | 0 | 2 (67) |
| Hearing impairment | 6 (5) | 0 | 0 | 0 | 1 (17) | 5 (11) | 0 | 0 | 0 |
| Seizure | 16 (12) | 4 (40) | 0 | 5 (11) | 2 (10) | 5 (11) | 0 | 0 | 0 |
GOS‐E Peds, Pediatric Version of the Glasgow Outcome Scale–Extended; HSVE, herpes simplex virus encephalitis; JEV, Japanese Encephalitis Virus; S. pneumoniae, Streptococcus pneumoniae; M. pneumoniae, Mycoplasma pneumoniae; C. albicans, Candida albicans; C. neoformans, Cryptococcus neoformans.
Other virus included mumps virus (N = 1), Epstein‐Barr virus (N = 4), Japanese encephalitis (N = 3) and probable viral meningitis and/or encephalitis (N = 37).
Other bacteria included Klebsiella pneumoniae (N = 2), Escherichia coli (N = 2), Streptococcus agalactiae (N = 2), Streptococcus intermedius (N = 2) and probable bacterial meningitis (N = 38).
Univariate analysis of factors associated with post‐encephalitic epilepsy
| Variables | Non‐PEE | PEE | PEE % |
| OR (95% |
|---|---|---|---|---|---|
| Numbers | 115 | 16 | 12.2 | ‐ | ‐ |
| Age (month) | 51 (1–180) | 28 (1–120) | ‐ | ‐ | ‐ |
| Sex | |||||
| Male | 82 | 10 | 10.9 | 0.67 | 0.67 (0.23–2.00) |
| Female | 33 | 6 | 15.4 | ||
| length of hospital stay (d) | 25.9 ± 19.0 | 37.9 ± 28.3 | ‐ | 0.12 | ‐ |
| Initial seizures during acute phase | |||||
| Yes | 54 | 16 | 22.9 | <0.01 | 1.30 (1.14–1.47) |
| No | 61 | 0 | 0.0 | ||
| Seizure frequency during acute phase | |||||
| Single | 16 | 1 | 5.9 | 0.06 | 1.06 (0.94–1.20) |
| Recurrent or Status epilepticus | 38 | 15 | 28.3 | <0.01 | 1.35 (1.18–1.65) |
| Coma during acute phase | |||||
| No | 97 | 12 | 11.0 | 0.56 | 1.80 (0.52–6.20) |
| Yes | 18 | 4 | 18.1 | ||
| Steroid treatment | |||||
| Yes | 41 | 5 | 11.9 | 0.73 | 1.22 (0.40–3.75) |
| No | 74 | 11 | 11.6 | ||
| HSVE | |||||
| Yes | 7 | 4 | 36.4 | 0.04 | 5.14 (1.31–20.15) |
| No | 108 | 12 | 10.0 | ||
| Pure spikes in electroencephalogram during acute phase | |||||
| No | 111 | 0 | 0.0 | <0.01 | 5.00 (2.28–12.01) |
| Yes | 4 | 16 | 80.0 | ||
| Parenchymal involvement in brain imaging | |||||
| No | 84 | 3 | 3.4 | <0.01 | 11.74 (3.13–44.01) |
| Yes | 31 | 13 | 29.6 | ||
PEE, post‐encephalitic epilepsy; HSVE, herpes simplex virus encephalitis; OR, odds ratio; CI, confidence interval; ‐, not done.